Monoclonal gammopathy of undetermined significance risk factors: Difference between revisions
| Line 12: | Line 12: | ||
* Non-IgG MGUS (ie, IgA, IgM, IgD MGUS) | * Non-IgG MGUS (ie, IgA, IgM, IgD MGUS) | ||
* Abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains <0.26 or >1.65) <ref name="pmid15855274">{{cite journal |vauthors=Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA |title=Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance |journal=Blood |volume=106 |issue=3 |pages=812–7 |date=August 2005 |pmid=15855274 |pmc=1895159 |doi=10.1182/blood-2005-03-1038 |url=}}</ref><ref name="pmid15491291">{{cite journal |vauthors=Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, Larson DR, Plevak MF, Katzmann JA |title=Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance |journal=Br. J. Haematol. |volume=127 |issue=3 |pages=308–10 |date=November 2004 |pmid=15491291 |doi=10.1111/j.1365-2141.2004.05169.x |url=}}</ref> | * Abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains <0.26 or >1.65) <ref name="pmid15855274">{{cite journal |vauthors=Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA |title=Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance |journal=Blood |volume=106 |issue=3 |pages=812–7 |date=August 2005 |pmid=15855274 |pmc=1895159 |doi=10.1182/blood-2005-03-1038 |url=}}</ref><ref name="pmid15491291">{{cite journal |vauthors=Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, Larson DR, Plevak MF, Katzmann JA |title=Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance |journal=Br. J. Haematol. |volume=127 |issue=3 |pages=308–10 |date=November 2004 |pmid=15491291 |doi=10.1111/j.1365-2141.2004.05169.x |url=}}</ref> | ||
* African Americans | |||
* Age | |||
* Male sex | |||
* Family History | |||
* History of immunosuppression | |||
* | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:05, 8 August 2018
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance risk factors On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance risk factors |
|
FDA on Monoclonal gammopathy of undetermined significance risk factors |
|
on Monoclonal gammopathy of undetermined significance risk factors |
|
Monoclonal gammopathy of undetermined significance risk factors in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance risk factors |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Common risk factors in the development of monoclonal gammopathy of undetermined significance include: serum monoclonal protein level ≥1.5 g/dL ,Non-IgG MGUS (ie, IgA, IgM, IgD MGUS),abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains <0.26 or >1.65.
Risk Factors
Common risk factors in the development of monoclonal gammopathy of undetermined significance include: serum monoclonal protein level ≥1.5 g/dL ,Non-IgG MGUS (ie, IgA, IgM, IgD MGUS),abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains <0.26 or >1.65.
Common Risk Factors
Common risk factors in the development of monoclonal gammopathy of undetermined significance include:[1][2][3]
- Levels of serum monoclonal protein ≥1.5 g/dL [4]
- Non-IgG MGUS (ie, IgA, IgM, IgD MGUS)
- Abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains <0.26 or >1.65) [5][6]
- African Americans
- Age
- Male sex
- Family History
- History of immunosuppression
References
- ↑ Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ (February 2002). "A long-term study of prognosis in monoclonal gammopathy of undetermined significance". N. Engl. J. Med. 346 (8): 564–9. doi:10.1056/NEJMoa01133202. PMID 11856795.
- ↑ Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, Maiolo AT (February 1996). "Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy". Blood. 87 (3): 912–8. PMID 8562962.
- ↑ Rosiñol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, Bladé J (April 2007). "Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size". Mayo Clin. Proc. 82 (4): 428–34. doi:10.4065/82.4.428. PMID 17418070.
- ↑ Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E (March 2002). "Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma". J. Clin. Oncol. 20 (6): 1625–34. doi:10.1200/JCO.2002.20.6.1625. PMID 11896113.
- ↑ Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA (August 2005). "Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance". Blood. 106 (3): 812–7. doi:10.1182/blood-2005-03-1038. PMC 1895159. PMID 15855274.
- ↑ Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, Larson DR, Plevak MF, Katzmann JA (November 2004). "Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance". Br. J. Haematol. 127 (3): 308–10. doi:10.1111/j.1365-2141.2004.05169.x. PMID 15491291.